deltatrials
Completed PHASE2 NCT01130597

Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease

A Multicenter, Open-Label, Single-Arm Study to Evaluate a Titration Regimen for Patiromer in Heart Failure Patients With Chronic Kidney Disease

Sponsor: Relypsa, Inc.

Conditions Heart Failure
Updated 7 times since 2017 Last updated: May 10, 2021 Started: May 31, 2010 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

Listed as NCT01130597, this PHASE2 trial focuses on Heart Failure and remains completed. Sponsored by Relypsa, Inc., it has been updated 7 times since 2010, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Change History

7 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jun 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jun 2021 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

Show 2 earlier versions
  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Relypsa, Inc.
Data source: Vifor Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • Golnik, Slovenia
  • Izola, Slovenia
  • Ljubljana, Slovenia
  • Maribor, Slovenia
  • Slovenj Gradec, Slovenia
  • Tbilisi, Georgia